A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Explore the implications of GLP-1 drugs in managing India's obesity crisis as experts warn of potential misuse and health ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

With Indias rising burden of diabetes and obesity, GLP-1 drugs may play a growing role in treatment. But the excitement must ...

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...